Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Carly T. Campbell"'
Autor:
Scott R. Daigle, Kathrin M. Bernt, Stephen J. Blakemore, Robert A. Copeland, Jesse J. Smith, Roy M. Pollock, Edward J. Olhava, Nigel J. Waters, Taylor Yamauchi, Michael J. Maria, Ty M. Thomson, David A. Drubin, Jessica N. Haladyna, Carly T. Campbell
Contains the mechanism footprint gene list referenced by supplemental Table S3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b27a0f3e74bce3707a37643b0d7252
https://doi.org/10.1158/1535-7163.22508665.v1
https://doi.org/10.1158/1535-7163.22508665.v1
Autor:
Scott R. Daigle, Kathrin M. Bernt, Stephen J. Blakemore, Robert A. Copeland, Jesse J. Smith, Roy M. Pollock, Edward J. Olhava, Nigel J. Waters, Taylor Yamauchi, Michael J. Maria, Ty M. Thomson, David A. Drubin, Jessica N. Haladyna, Carly T. Campbell
Contains supplemental methods, figures, and tables 1, 2, 3, and 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01e37128c2af18c9c04b6058c16e62d2
https://doi.org/10.1158/1535-7163.22508668
https://doi.org/10.1158/1535-7163.22508668
Autor:
Scott R. Daigle, Kathrin M. Bernt, Stephen J. Blakemore, Robert A. Copeland, Jesse J. Smith, Roy M. Pollock, Edward J. Olhava, Nigel J. Waters, Taylor Yamauchi, Michael J. Maria, Ty M. Thomson, David A. Drubin, Jessica N. Haladyna, Carly T. Campbell
Contains all pathways altered in NOMO-1 resistance identified by analysis with KEGG, GO - Biological Process, and MSigDB databases.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b453d4637f5db7e35f239ad2de2f6e28
https://doi.org/10.1158/1535-7163.22508662.v1
https://doi.org/10.1158/1535-7163.22508662.v1
Autor:
Sebastien Hazard, Stephen J. Blakemore, Tara Gelb, Heather Cohen, Carly T. Campbell, Phil Brandish, Kristen Hurov, Dominic P. Smethurst, Erinn Parnell, David Galbraith, Mate Nagy, Qingyan Au, Nicholas Keen, Dan Rozelle, Johanna Lahdenranta
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundBicycles are fully synthetic constrained peptides with antibody-like affinities that target selectively, readily penetrate tumor tissue, have relatively short half-lives, and can be chemically linked together to generate multifunctional mol
Autor:
Kevin McDonnell, Phil Jeffrey, Carly T. Campbell, Drasti Kanakia, Michael C Kelly, Johanna Lahdenranta, Jun Ma, Julia Kristensson, Heather B. Cohen, Elizabeth Repash, David Witty, Fanglei You, Punit Upadhyaya, Eric Haines, Philip E. Brandish, Kristen Hurov, Nicholas Keen, Stephen J. Blakemore
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
BackgroundCD137 (4-1BB) is an immune costimulatory receptor with high therapeutic potential in cancer. We are creating tumor target-dependent CD137 agonists using a novel chemical approach based on fully synthetic constrained bicyclic peptide (Bicycl
Autor:
Stephen J. Blakemore, Tara Gelb, Amy Dickson, Michael Rigby, Andrew J. McKenzie, Dan Rozelle, Sean Santos, Carly T. Campbell
Publikováno v:
Cancer Research. 81:391-391
Introduction: BT8009 consists of a bicyclic peptide targeting the tumor antigen Nectin-4, linked to the cytotoxin monomethyl auristatin E (MMAE) via a molecular spacer and cleavable linker. BT8009 is currently being investigated in a Phase 1/2 clinic
Autor:
Michael Rigby, Carly T. Campbell, Amy Dickson, Heather Cohen, Robert Smale, Josette William Ragheb, Tara Gelb, Pierre Lee, Shawn Watson, Stephen J. Blakemore
Publikováno v:
Cancer Research. 81:1197-1197
Introduction: Bicycles® are a novel class of fully synthetic, short, constrained peptides. BT8009 consists of a bicyclic peptide targeting the tumor antigen Nectin-4, linked to the cytotoxin monomethyl auristatin E (MMAE) via a molecular spacer and
Autor:
Kristen Hurov, Philip E. Brandish, Eric Haines, Nicholas Keen, Johanna Lahdenranta, Richard A. Klinghoffer, Carly T. Campbell, Punit Upadhyaya, Elizabeth Repash, Marc Grenley, Stephen J. Blakemore
Publikováno v:
Cancer Research. 81:1724-1724
A new generation of both systemic and targeted CD137 agonists are entering clinical development following agonistic anti-CD137 (4-1BB) antibody development nearly a decade ago. However, each of these molecules rely on biologic agents with potentially
Autor:
D. Smethurst, Gerald Steven Falchook, Phil Jeffrey, Roshawn Watson, Julius Kirui, Meredith McKean, Hendrik-Tobias Arkenau, Elisa Fontana, Mary-Anne McKenna, Johanna C. Bendell, Neil Palmisiano, Carly T. Campbell, Babar Bashir
Publikováno v:
Journal of Clinical Oncology. 39:TPS2668-TPS2668
TPS2668 Background: BT8009 is a Bicycle Toxin Conjugate (BTC), a novel class of chemically synthesized molecules, comprising a bicyclic peptide targeting Nectin-4 tumor antigen, linked to cytotoxin (monomethyl auristatin E [MMAE]) via a valine-citrul
Autor:
Nigel J. Waters, Angelos Dovletoglou, Tyler B. Jensen, Scott R. Daigle, Edward J. Olhava, Brett Franklin Truitt, Aravind Basavapathruni, Carly T. Campbell, Kim Stickland, Roy M. Pollock, Bruce N. Rehlaender
Publikováno v:
Journal of Controlled Release. 220:758-765
Protein methyltransferases are emerging as promising drug targets for therapeutic intervention in human cancers. Pinometostat (EPZ-5676) is a small molecule inhibitor of the DOT1L enzyme, a histone methyltransferase that methylates lysine 79 of histo